DK0750628T3 - Fibroblastvækstfaktor-10 - Google Patents
Fibroblastvækstfaktor-10Info
- Publication number
- DK0750628T3 DK0750628T3 DK95912829T DK95912829T DK0750628T3 DK 0750628 T3 DK0750628 T3 DK 0750628T3 DK 95912829 T DK95912829 T DK 95912829T DK 95912829 T DK95912829 T DK 95912829T DK 0750628 T3 DK0750628 T3 DK 0750628T3
- Authority
- DK
- Denmark
- Prior art keywords
- disclosed
- polypeptides
- fgf
- polypeptide
- growth factor
- Prior art date
Links
- 108090001047 Fibroblast growth factor 10 Proteins 0.000 title abstract 3
- 102000004864 Fibroblast growth factor 10 Human genes 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 abstract 2
- 230000004663 cell proliferation Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108091026890 Coding region Proteins 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 abstract 1
- 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000004075 alteration Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 102000057243 human FGF10 Human genes 0.000 abstract 1
- 210000003644 lens cell Anatomy 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 230000003961 neuronal insult Effects 0.000 abstract 1
- 238000010188 recombinant method Methods 0.000 abstract 1
- 230000000250 revascularization Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/207,412 US5817485A (en) | 1994-03-08 | 1994-03-08 | Nucleic acids and cells for recombinant production of fibroblast growth factor-10 |
| PCT/US1995/002950 WO1995024414A1 (en) | 1994-03-08 | 1995-03-08 | Fibroblast growth factor-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0750628T3 true DK0750628T3 (da) | 2004-02-02 |
Family
ID=22770445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK95912829T DK0750628T3 (da) | 1994-03-08 | 1995-03-08 | Fibroblastvækstfaktor-10 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US5817485A (no) |
| EP (2) | EP1380594A1 (no) |
| JP (2) | JPH09510103A (no) |
| CN (1) | CN1150804A (no) |
| AT (1) | ATE251637T1 (no) |
| AU (1) | AU1986195A (no) |
| CA (1) | CA2183961A1 (no) |
| CZ (1) | CZ260696A3 (no) |
| DE (1) | DE69531892T2 (no) |
| DK (1) | DK0750628T3 (no) |
| ES (1) | ES2208676T3 (no) |
| FI (1) | FI963475A (no) |
| HU (1) | HUT77578A (no) |
| IL (1) | IL112878A0 (no) |
| MX (1) | MX9603897A (no) |
| NO (1) | NO963728L (no) |
| PL (1) | PL316202A1 (no) |
| PT (1) | PT750628E (no) |
| SK (1) | SK112996A3 (no) |
| WO (1) | WO1995024414A1 (no) |
| ZA (1) | ZA951886B (no) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7186688B1 (en) | 1994-03-08 | 2007-03-06 | Human Genome Sciences, Inc. | Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2 |
| US5932540A (en) | 1994-03-08 | 1999-08-03 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
| EP0751992B1 (en) | 1994-03-08 | 2005-11-09 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
| US6040157A (en) * | 1994-03-08 | 2000-03-21 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
| US6734285B2 (en) | 1994-03-08 | 2004-05-11 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 proteins and compositions |
| US6608182B1 (en) | 1994-03-08 | 2003-08-19 | Human Genome Sciences, Inc. | Human vascular endothelial growth factor 2 |
| US7109308B1 (en) | 1994-03-08 | 2006-09-19 | Human Genome Sciences, Inc. | Antibodies to human vascular endothelial growth factor 2 |
| US7153827B1 (en) | 1994-03-08 | 2006-12-26 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 and methods of use |
| US5693775A (en) * | 1995-05-12 | 1997-12-02 | The Johns Hopkins University School Of Medicine | Fibroblast growth factor homologous factor-1 (FHF-1) and methods of use |
| EP0832216A4 (en) * | 1995-06-05 | 1999-06-16 | Human Genome Sciences Inc | FIBROBLAST GROWTH FACTOR 15 |
| US5773252A (en) | 1995-06-05 | 1998-06-30 | Human Genome Sciences, Inc. | Fibroblast growth factor 15 |
| US6020189A (en) * | 1996-08-30 | 2000-02-01 | The Johns Hopkins University School Of Medicine | Fibroblast growth factor homologous factors (FHFs) and methods of use |
| US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
| US8212004B2 (en) | 1999-03-02 | 2012-07-03 | Human Genome Sciences, Inc. | Neutrokine-alpha fusion proteins |
| JPH10279501A (ja) * | 1997-02-10 | 1998-10-20 | Rohto Pharmaceut Co Ltd | 育毛剤 |
| US6335317B1 (en) * | 1998-04-10 | 2002-01-01 | Emory University | Use of gut-trophic growth factors to improve oxidative status |
| US7223724B1 (en) | 1999-02-08 | 2007-05-29 | Human Genome Sciences, Inc. | Use of vascular endothelial growth factor to treat photoreceptor cells |
| AU5440800A (en) * | 1999-05-21 | 2000-12-12 | Human Genome Sciences, Inc. | Fibroblast growth factor 10 |
| AU2001268427B2 (en) | 2000-06-16 | 2007-03-29 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to blys |
| US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
| WO2002011769A1 (en) | 2000-08-04 | 2002-02-14 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
| US20030091565A1 (en) | 2000-08-18 | 2003-05-15 | Beltzer James P. | Binding polypeptides and methods based thereon |
| EP1385864B1 (en) | 2001-04-13 | 2010-06-09 | Human Genome Sciences, Inc. | Anti-VEGF-2 antibodies |
| US7402312B2 (en) | 2001-04-13 | 2008-07-22 | Human Genome Sciences, Inc. | Antibodies to vascular endothelial growth factor 2 (VEGF-2) |
| US20060183712A1 (en) * | 2005-02-17 | 2006-08-17 | The Texas A&M University System | Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor |
| US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| US8211649B2 (en) | 2006-03-31 | 2012-07-03 | Human Genome Sciences, Inc. | Methods of diagnosing and prognosing hodgkin's lymphoma |
| KR101187871B1 (ko) | 2009-09-23 | 2012-10-05 | (주)케어젠 | Ｆｇｆ１０－유래 펩타이드 및 그의 용도 |
| EP2643693A2 (en) * | 2010-11-23 | 2013-10-02 | KCI Licensing, Inc. | Devices and methods for the diagnosis and treatment of wounds using biomarkers |
| CN103169658A (zh) * | 2012-10-26 | 2013-06-26 | 温州医学院 | 成纤维细胞生长因子-10脂质体制备及在毛发再生中的应用 |
| EP4183796A1 (en) | 2021-11-19 | 2023-05-24 | Enantis s.r.o. | Thermostable fgf10 polypeptide or fragment thereof use thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5155214A (en) * | 1984-03-05 | 1992-10-13 | The Salk Institute For Biological Studies | Basic fibroblast growth factor |
| US4868113A (en) * | 1986-03-03 | 1989-09-19 | Rorer Biotechnology, Inc. | Recombinant DNA vector encoding human endothelial cell growth factor |
| JP3303211B2 (ja) * | 1991-04-26 | 2002-07-15 | 武田薬品工業株式会社 | ｂＦＧＦムテインおよびその製造法 |
| AU4995193A (en) * | 1992-08-04 | 1994-03-03 | Regeneron Pharmaceuticals, Inc. | Method of enhancing differentiation and survival of neuronal precursor cells |
-
1994
- 1994-03-08 US US08/207,412 patent/US5817485A/en not_active Expired - Fee Related
-
1995
- 1995-03-03 IL IL11287895A patent/IL112878A0/xx unknown
- 1995-03-07 ZA ZA951886A patent/ZA951886B/xx unknown
- 1995-03-08 JP JP7523645A patent/JPH09510103A/ja not_active Ceased
- 1995-03-08 DE DE69531892T patent/DE69531892T2/de not_active Expired - Fee Related
- 1995-03-08 ES ES95912829T patent/ES2208676T3/es not_active Expired - Lifetime
- 1995-03-08 CA CA002183961A patent/CA2183961A1/en not_active Abandoned
- 1995-03-08 EP EP03022286A patent/EP1380594A1/en not_active Withdrawn
- 1995-03-08 CN CN95192340A patent/CN1150804A/zh active Pending
- 1995-03-08 WO PCT/US1995/002950 patent/WO1995024414A1/en active IP Right Grant
- 1995-03-08 AU AU19861/95A patent/AU1986195A/en not_active Abandoned
- 1995-03-08 CZ CZ962606A patent/CZ260696A3/cs unknown
- 1995-03-08 AT AT95912829T patent/ATE251637T1/de not_active IP Right Cessation
- 1995-03-08 PL PL95316202A patent/PL316202A1/xx unknown
- 1995-03-08 HU HU9602434A patent/HUT77578A/hu unknown
- 1995-03-08 SK SK1129-96A patent/SK112996A3/sk unknown
- 1995-03-08 MX MX9603897A patent/MX9603897A/es unknown
- 1995-03-08 EP EP95912829A patent/EP0750628B1/en not_active Expired - Lifetime
- 1995-03-08 PT PT95912829T patent/PT750628E/pt unknown
- 1995-03-08 DK DK95912829T patent/DK0750628T3/da active
-
1996
- 1996-09-05 FI FI963475A patent/FI963475A/fi not_active Application Discontinuation
- 1996-09-06 NO NO963728A patent/NO963728L/no unknown
-
2001
- 2001-07-12 US US09/902,773 patent/US20020034787A1/en not_active Abandoned
-
2002
- 2002-03-05 JP JP2002058893A patent/JP2002335982A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP0750628B1 (en) | 2003-10-08 |
| FI963475A (fi) | 1996-11-05 |
| ZA951886B (en) | 1996-09-09 |
| PL316202A1 (en) | 1996-12-23 |
| SK112996A3 (en) | 1997-01-08 |
| DE69531892D1 (de) | 2003-11-13 |
| WO1995024414A1 (en) | 1995-09-14 |
| PT750628E (pt) | 2004-03-31 |
| CN1150804A (zh) | 1997-05-28 |
| JPH09510103A (ja) | 1997-10-14 |
| DE69531892T2 (de) | 2004-07-22 |
| NO963728L (no) | 1996-11-07 |
| IL112878A0 (en) | 1995-06-29 |
| EP1380594A1 (en) | 2004-01-14 |
| JP2002335982A (ja) | 2002-11-26 |
| US20020034787A1 (en) | 2002-03-21 |
| ES2208676T3 (es) | 2004-06-16 |
| EP0750628A4 (en) | 1997-06-11 |
| CZ260696A3 (en) | 1997-05-14 |
| AU1986195A (en) | 1995-09-25 |
| EP0750628A1 (en) | 1997-01-02 |
| CA2183961A1 (en) | 1995-09-14 |
| ATE251637T1 (de) | 2003-10-15 |
| FI963475A0 (fi) | 1996-09-05 |
| NO963728D0 (no) | 1996-09-06 |
| HUT77578A (hu) | 1998-06-29 |
| MX9603897A (es) | 1997-07-31 |
| US5817485A (en) | 1998-10-06 |
| HU9602434D0 (en) | 1996-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0750628T3 (da) | Fibroblastvækstfaktor-10 | |
| ATE347595T1 (de) | Menschlicher wachstumsfaktor 2, spezifisch für vaskuläre endothelzellen | |
| ATE354638T1 (de) | Menschlicher gewebsinhibitor von metalloproteinase-4 | |
| ATE430197T1 (de) | Fibroblasten wachstumsfaktor-ähnliche polypeptide | |
| DE69530944D1 (de) | Keratinozyten-wachstumsfaktor 2 | |
| DE68923107D1 (de) | DNA-Sequenzen, rekombinante DNA-Moleküle und Verfahren zur Herstellung von Lipocortin III, IV, V, und VI. | |
| FI863626A (fi) | Dna-sekvenser, rekombinant-dna -molekyler och foerfaranden foer framstaellning av polypeptider som liknar humant lipokortin. | |
| ES2151557T3 (es) | Corpusculos de proteinas de estaño, estanniocalcina. | |
| ATE300554T1 (de) | Bindegewebe-wachstumsfaktor 3. | |
| MX9708493A (es) | Factor 15 de crecimiento de fibroblastos. | |
| MX9706854A (es) | Factor 14 de crecimiento de fibroblastos. | |
| MX9709217A (es) | Factor de crecimiento 13 de fibroblastos. | |
| ATE257486T1 (de) | Wachstumsfördernde proteine und peptide für epithelzellen von nieren | |
| MX9707897A (es) | Factor-11 del crecimiento de fibroblastos. | |
| MX9706204A (es) | Factor 2 de crecimiento de queratinocitos. | |
| MX9709570A (es) | Factor de crecimiento 3 endotelial, vascular, humano. |